Globus Medical, Inc. (GMED) Key Metrics
GMED valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $10.30B
- Enterprise value
- $9.45B
- P/E (TTM)
- 19.7 10-yr median 39.4
- Forward P/E
- 13.9
- PEG ratio
- 1.73
- Price / sales
- 3.3 10-yr median 6.2
- Price / book
- 2.1 10-yr median 3.9
- EV / EBITDA
- 9.9 10-yr median 20.9
- Dividend yield
- —
- Beta
- 0.96
GMED key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGMED valuation Price multiples at each fiscal year-end price.
GMED returns How much profit the business earns on the capital it uses.
GMED per-share figures Results divided by the shares outstanding at year-end.
GMED financial health Debt, liquidity and how easily interest is covered.
GMED efficiency & capital use Working capital cycle and where the cash goes.
GMED valuation history
GMED returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GMED debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GMED cash returned to shareholders
GMED price vs earnings per share
GMED key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $11.98B | $11.40B | $6.11B | $7.62B | $7.48B | $6.59B | $6.01B | $4.38B | $4.02B | $2.39B |
| Enterprise value | $11.54B | $11.05B | $6.11B | $7.18B | $7.04B | $6.16B | $5.70B | $4.05B | $3.65B | $2.10B |
| P/E ratio | 22.3 | 110.7 | 49.7 | 40.1 | 50.1 | 64.4 | 38.7 | 28.0 | 37.5 | 22.9 |
| Price / sales | 4.1 | 4.5 | 3.9 | 7.5 | 7.8 | 8.3 | 7.6 | 6.2 | 6.3 | 4.2 |
| Price / book | 2.6 | 2.7 | 1.5 | 4.1 | 4.3 | 4.4 | 4.3 | 3.7 | 4.2 | 2.9 |
| Price / free cash flow | 20.3 | 28.1 | 37.0 | 73.0 | 34.1 | 48.7 | 59.3 | 36.0 | 37.2 | 18.3 |
| Price / operating cash flow | 15.9 | 21.9 | 25.1 | 42.7 | 27.1 | 33.1 | 34.9 | 24.1 | 25.2 | 13.9 |
| EV / sales | 3.9 | 4.4 | 3.9 | 7.0 | 7.4 | 7.8 | 7.3 | 5.7 | 5.7 | 3.7 |
| EV / EBITDA | 13.0 | 23.3 | 17.6 | 23.6 | 26.6 | 34.6 | 24.8 | 18.5 | 17.8 | 10.9 |
| EV / free cash flow | 19.6 | 27.3 | 37.0 | 68.8 | 32.1 | 45.6 | 56.3 | 33.2 | 33.7 | 16.0 |
| Earnings yield | 4.5% | 0.9% | 2.0% | 2.5% | 2.0% | 1.6% | 2.6% | 3.6% | 2.7% | 4.4% |
| Free cash flow yield | 4.9% | 3.6% | 2.7% | 1.4% | 2.9% | 2.1% | 1.7% | 2.8% | 2.7% | 5.5% |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 2.5% | 0.8% | 3.7% | 1.9% | 0.0% | 1.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Share price at fiscal year-end | $87.31 | $82.71 | $53.29 | $74.27 | $72.20 | $65.22 | $58.88 | $43.28 | $41.10 | $24.81 |
| Per share | ||||||||||
| Revenue per share | $21.42 | $18.27 | $13.68 | $9.97 | $9.25 | $7.81 | $7.70 | $7.04 | $6.50 | $5.85 |
| Earnings per share | $3.92 | $0.75 | $1.07 | $1.85 | $1.44 | $1.01 | $1.52 | $1.54 | $1.10 | $1.08 |
| Operating cash flow per share | $5.49 | $3.78 | $2.12 | $1.74 | $2.67 | $1.97 | $1.69 | $1.79 | $1.63 | $1.78 |
| Free cash flow per share | $4.29 | $2.94 | $1.44 | $1.02 | $2.12 | $1.34 | $0.99 | $1.20 | $1.11 | $1.36 |
| Cash per share | $4.06 | $6.46 | $4.52 | $4.35 | $4.28 | $4.23 | $3.05 | $3.35 | $3.82 | $3.01 |
| Book value per share | $33.33 | $30.30 | $34.88 | $17.99 | $16.81 | $14.92 | $13.75 | $11.70 | $9.89 | $8.63 |
| Tangible book value per share | $17.44 | $14.14 | $14.30 | $15.45 | $14.41 | $12.50 | $11.71 | $9.62 | $7.82 | $6.89 |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | $0.00 |
| Capex per share | $1.20 | $0.84 | $0.68 | $0.72 | $0.55 | $0.63 | $0.69 | $0.59 | $0.52 | $0.42 |
| Debt per share | $0.86 | $3.90 | $4.54 | $0.06 | $0.05 | $0.05 | $0.02 | $0.04 | $0.00 | $0.00 |
| Shares outstanding | 137.2M | 137.9M | 114.6M | 102.6M | 103.6M | 101.0M | 102.0M | 101.3M | 97.9M | 96.4M |
| Change in shares outstanding | −0.5% | +20.3% | +11.7% | −0.9% | +2.6% | −1.0% | +0.7% | +3.5% | +1.5% | +0.4% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 12.3% | 2.5% | 4.2% | 10.6% | 9.2% | 7.0% | 12.0% | 14.5% | 11.9% | 13.5% |
| Return on invested capital (ROIC) | 10.6% | 3.6% | 3.7% | 13.2% | 11.9% | 8.3% | 14.5% | 19.5% | 18.0% | 21.0% |
| Return on assets (ROA) | 10.2% | 2.0% | 3.4% | 9.4% | 8.2% | 6.4% | 11.0% | 13.2% | 10.7% | 11.8% |
| Return on tangible assets | 17.2% | 3.4% | 4.5% | 10.5% | 8.7% | 7.1% | 11.7% | 14.4% | 12.3% | 13.7% |
| Free cash flow margin | 20.0% | 16.1% | 10.5% | 10.2% | 22.9% | 17.1% | 12.9% | 17.1% | 17.0% | 23.2% |
| Income quality (OCF / net income) | 1.40 | 5.06 | 1.98 | 0.94 | 1.85 | 1.94 | 1.11 | 1.16 | 1.49 | 1.65 |
| Financial health | ||||||||||
| Total debt | $118.7M | $537.2M | $520.4M | $6.0M | $5.1M | $4.8M | $2.5M | $4.5M | $0 | $0 |
| Cash & short-term investments | $557.2M | $890.1M | $517.8M | $446.1M | $443.4M | $426.7M | $311.5M | $339.7M | $373.7M | $290.3M |
| Net debt | −$438.6M | −$352.9M | $2.6M | −$440.0M | −$438.4M | −$421.9M | −$309.0M | −$335.2M | −$373.7M | −$290.3M |
| Debt / equity | 0.03 | 0.13 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / assets | 0.02 | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net debt / EBITDA | −0.49 | −0.74 | 0.01 | −1.45 | −1.66 | −2.37 | −1.35 | −1.53 | −1.82 | −1.50 |
| Current ratio | 4.26 | 2.54 | 4.88 | 6.18 | 6.17 | 6.80 | 6.17 | 6.56 | 6.67 | 6.43 |
| Quick ratio | 2.74 | 1.77 | 2.72 | 4.30 | 4.48 | 4.91 | 4.41 | 5.20 | 5.50 | 5.02 |
| Interest coverage | — | 39.6 | 6.6 | 16.0 | 18.5 | 8.0 | 9.9 | 12.8 | 24.5 | 50.4 |
| Working capital | $1.63B | $1.32B | $1.52B | $824.1M | $724.4M | $701.0M | $576.1M | $534.6M | $527.3M | $433.9M |
| Invested capital | $4.13B | $3.82B | $4.00B | $1.41B | $1.30B | $1.08B | $1.09B | $850.3M | $594.1M | $541.8M |
| Tangible asset value | $2.39B | $1.95B | $1.64B | $1.59B | $1.49B | $1.26B | $1.19B | $974.5M | $765.2M | $664.4M |
| Net current asset value | $1.40B | $1.10B | $827.2M | $753.6M | $648.6M | $648.6M | $557.8M | $515.5M | $509.6M | $418.2M |
| Graham number | $54.22 | $22.57 | $29.00 | $27.38 | $23.33 | $18.44 | $21.70 | $20.16 | $15.62 | $14.49 |
| Graham net-net per share | $5.58 | $4.20 | $2.03 | $5.15 | $4.54 | $4.75 | $3.94 | $3.93 | $4.21 | $3.35 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | $300.5M | $85.8M | $225.6M | $144.5M | $0 | $104.7M | $0 | $0 | $0 | $0 |
| Dividend payout ratio | — | — | — | — | — | — | — | — | 0.0% | 0.0% |
| Dividends + buybacks / free cash flow | 51.0% | 21.2% | 136.5% | 138.4% | 0.0% | 77.5% | 0.0% | 0.0% | 0.0% | 0.0% |
| Capex / revenue | 5.6% | 4.6% | 5.0% | 7.2% | 5.9% | 8.1% | 9.0% | 8.4% | 8.1% | 7.3% |
| Capex / operating cash flow | 21.9% | 22.2% | 32.1% | 41.5% | 20.6% | 32.0% | 41.1% | 32.9% | 32.2% | 23.8% |
| Capex / depreciation | 0.59 | 0.45 | 0.54 | 1.08 | 0.81 | 1.01 | 1.34 | 1.43 | 1.22 | 1.06 |
| Stock-based compensation / revenue | 1.7% | 2.2% | 3.4% | 3.2% | 3.2% | 3.4% | 3.3% | 3.1% | 2.3% | 2.0% |
| R&D / revenue | 6.3% | 6.5% | 7.9% | 7.1% | 10.2% | 10.7% | 7.6% | 7.8% | 6.9% | 7.9% |
| SG&A / revenue | 40.1% | 38.9% | 41.0% | 42.2% | 42.6% | 45.0% | 45.2% | 43.7% | 42.1% | 39.4% |
| Efficiency | ||||||||||
| Days sales outstanding | 82.1 | 78.5 | 84.0 | 68.3 | 59.8 | 71.8 | 71.3 | 69.5 | 63.9 | 58.9 |
| Days of inventory on hand | 270.3 | 265.7 | 381.9 | 370.9 | 355.6 | 357.1 | 332.2 | 274.4 | 268.2 | 295.3 |
| Days payables outstanding | 33.1 | 23.2 | 30.9 | 40.2 | 30.6 | 35.9 | 51.2 | 58.3 | 51.6 | 45.3 |
| Cash conversion cycle (days) | 319.2 | 320.9 | 435.0 | 399.1 | 384.7 | 392.9 | 352.2 | 285.5 | 280.6 | 308.9 |
| Receivables turnover | 4.45 | 4.65 | 4.34 | 5.34 | 6.11 | 5.08 | 5.12 | 5.25 | 5.71 | 6.19 |
| Payables turnover | 11.01 | 15.71 | 11.82 | 9.09 | 11.91 | 10.16 | 7.13 | 6.26 | 7.08 | 8.06 |
| Inventory turnover | 1.35 | 1.37 | 0.96 | 0.98 | 1.03 | 1.02 | 1.10 | 1.33 | 1.36 | 1.24 |
| Asset turnover | 0.56 | 0.49 | 0.44 | 0.51 | 0.53 | 0.49 | 0.55 | 0.60 | 0.63 | 0.64 |
| Average receivables | $661.0M | $541.6M | $361.1M | $191.5M | $156.9M | $155.3M | $153.4M | $135.7M | $111.4M | $91.1M |
| Average payables | $87.0M | $65.9M | $46.4M | $29.0M | $20.1M | $21.4M | $25.3M | $25.5M | $21.3M | $16.7M |
| Average inventory | $709.3M | $753.7M | $573.6M | $268.0M | $233.1M | $212.7M | $163.8M | $119.8M | $110.6M | $109.0M |
| Intangibles / total assets | 41.1% | 42.4% | 46.4% | 12.6% | 12.7% | 14.5% | 13.5% | 16.2% | 18.8% | 18.1% |
Computed from GMED's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GMED valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Globus Medical traded at 22.3 times earnings, against a 10-year median of 39.4. Based on the latest twelve months, the trailing P/E is 19.7 and the forward P/E is 13.9. Globus Medical earned a return on equity of 12.3% and a return on invested capital of 10.6% in fiscal 2025. It ended the year with $118.7 million of debt and $557.2 million in cash and short-term investments, a net cash position of $438.6 million. It returned $300.5 million to shareholders: $0 in dividends and $300.5 million in share buybacks, 51% of free cash flow. The share count rose 42.3% from 96.4M to 137.2M over 9 years.
See the GMED income statement, the GMED chart for price history, or the GMED stock overview for the latest quote and news.
GMED key metrics FAQ
What is Globus Medical's P/E ratio?
Globus Medical's trailing P/E ratio is 19.7 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 13.9. At the end of fiscal 2025 it was 22.3, compared with a 10-year median of 39.4.
What is Globus Medical's EV/EBITDA?
Globus Medical's enterprise value was 13.0 times EBITDA at the end of fiscal 2025 (enterprise value $11.5 billion, EBITDA $886.7 million); the current EV/EBITDA is 9.9.
What is Globus Medical's return on equity?
Globus Medical's return on equity (ROE) was 12.3% in fiscal 2025: net income of $537.9 million on average shareholders' equity of $4.4 billion.
What is Globus Medical's ROIC?
Globus Medical's return on invested capital was 10.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Globus Medical have?
Globus Medical had total debt of $118.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
Does Globus Medical buy back its shares?
Yes. Globus Medical spent $300.5 million on net share repurchases in fiscal 2025 Shares outstanding changed −0.5% over the year, to 137.2M..
What is Globus Medical's free cash flow yield?
Globus Medical generated $588.8 million of free cash flow in fiscal 2025, a free cash flow yield of 4.9% on its market value at year-end ($12.0 billion).
What is Globus Medical's current ratio?
Globus Medical's current ratio was 4.26 at the end of fiscal 2025: current assets were 4.26 times current liabilities.